ArticleJournal of the American Heart Association2026
Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Heart Failure and Chronic Kidney Disease.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEvidence comparing intermediate-term outcomes of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) in patients with concomitant heart failure and chronic kidney disease remains limited.
methodsUsing the TriNetX Global Collaborative Network, we conducted a retrospective study of adults with heart failure and chronic kidney disease undergoing TAVI or SAVR between January 2020 and December 2025. We excluded patients with redo procedures, history of endocarditis, prior heart transplant, ventricular assist device placement, or concomitant valve surgery. The primary outcome was all-cause death. Secondary outcomes included acute myocardial infarction, ischemic stroke, acute kidney injury, and all-cause hospitalization. Outcomes were assessed over 2 years of follow-up using Cox proportional hazards models.
resultsBefore matching, 9575 patients underwent TAVI and 1233 underwent SAVR. Propensity score matching across 21 covariates balanced demographics, comorbidities, medications, and laboratory values, yielding 1034 matched patients in each cohort. During follow-up, TAVI was associated with a higher mortality rate (hazard ratio [HR], 1.56 [95% CI, 1.21-2.01]) and lower risk of acute kidney injury (HR, 0.69 [95% CI, 0.60-0.80]) compared with SAVR. Risks of acute myocardial infarction (HR, 1.12 [95% CI, 0.87-1.44]), ischemic stroke (HR, 1.11 [95% CI, 0.85-1.45]), and all-cause hospitalization (HR, 0.90 [95% CI, 0.81-1.00]) were similar. Sensitivity analyses across alternative modeling strategies yielded directionally consistent results.
conclusionsIn this contemporary-era cohort of patients with heart failure and chronic kidney disease, SAVR was associated with a lower mortality rate, whereas TAVI was associated with less acute kidney injury. These findings suggest important trade-offs between procedural strategies in high-risk cardiorenal populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.